IGC-1C

IGC-1C is a cyclic dipeptide-based small-molecule modulator developed by IGC Pharma. It represents a novel approach to treating neurodegenerative and metabolic disorders, particularly Alzheimer's disease and obesity. Mechanistically, IGC-1C acts by inhibiting tau protein condensates formed via zinc-induced liquid-liquid phase separation (LLPS), thereby preventing their transition into toxic fibrils—a key process in the formation of neurofibrillary tangles associated with Alzheimer’s pathology. Preclinical studies show that IGC-1C binds tau with high affinity (Kd ~3.95 μM), supporting its potential as a therapeutic agent for tauopathies[2][1]. Additionally, AI-driven research has identified IGC-1C as a potential glucagon-like peptide 1 (GLP-1) receptor agonist, suggesting possible applications in weight loss and metabolic disorders alongside its neuroprotective effects[2][3][5]. The drug is currently in preclinical development.